Pharmacological research
Cure8 research brief
Why This Matters
Hypoxia-responsive biology may link epithelial, immune and microbial pathways that drive chronic inflammation and fibrosis in IBD, suggesting new therapeutic targets beyond classic anti-inflammatory drugs.
Who Should Pay Attention
Researchers and clinicians focused on IBD pathogenesis and drug discovery; patients and caregivers interested in emerging mechanistic research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a review article proposing that hypoxia (low tissue oxygen) is not just a consequence of intestinal inflammation but a central regulator linking epithelial cells, immune responses, stromal remodelling, and the microbiome in IBD.
The authors summarize data from single-cell and spatial transcriptomics, microbiome research, and metabolic studies to argue that hypoxia shapes niches that can sustain chronic inflammation and drive fibrosis.
They highlight mechanisms including hypoxia-responsive signalling, immunometabolism, microbial metabolites (short-chain fatty acids, succinate), iron metabolism and ferroptosis, and discuss potential pharmacologic targeting of hypoxia pathways.
The review emphasizes the need for cell- and isoform-selective approaches, sufficient tissue exposure, and long-term safety assessment before translation.
Keep In Mind
Abstract-level review synthesizing single-cell, spatial and microbiome studies; not a clinical trial or new patient-level data. Translation to therapies will require careful testing of selectivity, tissue exposure, and safety.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPharmacological research
AuthorsM Victoria Sánchez Luque, Abel Santiago Amador Moreno, María Elena Angarita-Planchez +5 more
InstitutionDepartment of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville. Seville, 41009. Spain.
Study typeJournal article, review
Indexed viaPubMed
Source typeResearch paper
PublishedNov 5, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of Competing Interest The authors declare no conflicts of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Inflammatory Bowel Disease: From Multifactorial and Metabolic Pathogenesis to Systemic Disease and Precision Medicine
This review reframes IBD as a systemic disease influenced by gut microbes, metabolism, and immune interactions — which matters because it points toward better ways to stratify patients, monitor disease, and personalize...
Macrophage plasticity as a therapeutic target in inflammatory bowel disease: Immunomodulatory and regenerative strategies.
Macrophages are central regulators of intestinal inflammation and repair; understanding their diversity and how to modulate them could lead to new, more targeted treatments for Crohn's disease and ulcerative colitis.
Microbial metabolic memory in inflammatory bowel disease: microbiota-derived metabolites, host-microbe reprogramming, and relapse susceptibility.
This review may help patients and clinicians understand how long-lasting changes in bacterial metabolism could contribute to IBD relapse and point toward future microbiome-targeted therapies aimed at restoring resilient...